Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022

SAN DIEGO, Nov. 2, 2022

SAN DIEGO, Nov. 2, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs will be presenting at the Emerging Growth Conference on November 9, 2022 (https://emerginggrowth.com/conference/).

This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr. David Koos, in real time.  Please ask your questions during the event and Dr. Koos and his team will do their best to get through as many of them as possible.

"As our portfolio of therapeutics mature, I am excited that we can get our message out to the public via this conference," says Dr. David Koos, CEO and Chairman of the Company.  "We have a loyal and enthusiastic shareholder base and I am always looking for ways to keep them updated on our progress."

Regen BioPharma, Inc. will be presenting from 1:45 - 2:15 Eastern time on Wednesday, November 9, 2022.  Please register here to ensure you are able to attend the conference and receive any updates that are released: https://goto.webcasts.com/starthere.jsp?ei=1575087&tp_key=8f326a607b&sti=rgbp 

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com.

About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.